Drawing for CAELIMIR

USPTO serial 79406277

CAELIMIR

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
PEISECKI, MARK A
Law office
TMEG LAW OFFICE 105

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with CAELIMIR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
009Software relating to the pharmaceutical field; bioinformatics software; healthcare software; software relating to the medical field; software relating to research, discovery and development of pharmaceuticals, therapeutics and/or diagnostics; electronic databases for capturing, storing, processing, evaluating and reproducing pharmaceutical data; all of the aforementioned goods whether or not including artificial intelligence.ACTIVE—
042Providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing pharmaceutical data; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring bioinformatics software; scientific computer programming services; pharmaceutical research and development; research and development of mRNA-based therapeutics; research and development of mRNA-based diagnostics; research and development of mRNA drugs; research and development in the field of microorganisms and cells; pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; development of gene-based medicines; laboratory research services relating to pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; services for assessing the efficiency of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; chemical research and analysis services; medical and pharmacological research services; scientific research for medical purposes; research and development in the field of diagnostic preparations; genetic research; genetic mapping for scientific purposes; providing scientific information in the field of medical disorders and their treatment; biotechnological research; biochemical research and development; research and development of vaccines; pharmaceutical drug discovery and development services; all of the aforementioned services whether or not including artificial intelligence; platform as a Service (PaaS), Software as a Service (SaaS) and/or Data as a Service (DaaS) in relation to all the aforementioned services.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 22, 2026FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 12, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 10, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 7, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 7, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 26, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 9, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 9, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Nov 14, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 10, 2025MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 10, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 12, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 28, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 25, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 25, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 19, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 19, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 13, 2025DOCKASSIGNED TO EXAMINER—
Oct 11, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 11, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance